Free Trial

This company has been marked as potentially delisted and may not be actively trading.

G1 Therapeutics (GTHX) News Today

G1 Therapeutics logo

GTHX Latest News

Drug developer seeks $100M for new cancer treatment
G1 Therapeutics Inc.
Hold Rating Affirmed Amid G1 Therapeutics’ Acquisition by Pharmacosmos
Needham Downgrades G1 Therapeutics (GTHX)
G1 Therapeutics (NASDAQ:GTHX) Downgraded by Wedbush
RTP company taken private in $405 million deal
G1 Therapeutics To Be Acquired By Pharmacosmos For $7.15/shr In Cash
G1 Therapeutics Q2 2024 Earnings Preview
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
Pharmacosmos Group to Acquire G1 Therapeutics
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
Get G1 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

GTHX Media Mentions By Week

GTHX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GTHX
News Sentiment

0.00

0.58

Average
Medical
News Sentiment

GTHX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GTHX Articles
This Week

0

1

GTHX Articles
Average Week

Get G1 Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:GTHX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners